During the Forbes Healthcare Summit, BIO CEO Jim Greenwood joined Gregg Stebben, host of ForbesBooks Radio, for a discussion about innovation taking place in the biopharma industry, the cost and value of prescription medicines and how the recent midterm elections may impact the drug pricing debate…

Writing for The Hill, BIO President and CEO Jim Greenwood tackled the drug pricing debate in Washington and touched on President Trump’s proposals for lowering drug prices. On the Administration’s recent International Pricing Index (IPI), which would move from a market-based payment formula for…

Once again, Blue Cross Blue Shield is out with a report attempting to stoke fear and confusion about prescription drug costs. And once again (because we’ve chronicled it before) what the major insurance company has to say is contradicted by its own pharmacy benefits manager. These drug cost…

The Centers for Medicare & Medicaid Services (CMS) has reversed a long-standing policy allowing Medicare Advantage plans to impose “step therapy” requirements for physician-administered drugs – also known as Medicare Part B. More accurately described as “fail first,” this dangerous policy will…

A new report by the Office of Inspector General at the U.S. Department of Health and Human Services (HHS) reaffirms concerns with a regulatory decision that undermines the health and well-being of America’s seniors. In an abrupt reversal of long-standing policy, the Centers for Medicare &…

Bloomberg has authored an investigative piece exposing drug cost middlemen, better known as pharmacy benefit managers (PBMs), for their role in marking up prices for common drugs and pocketing the difference. At issue is a little-known tactic called “spread pricing”, a strategy designed to pad the…

At a time when prescription drug prices and spending are remarkably stable, patients are getting hit harder than ever by flawed policies and poor decisions by some within the health care system. Surprise Billing In case you missed it, a Texas high school teacher named Drew Calver suffered from a…

A featured story by PBS NewsHour reaffirms that insurance companies and drug cost middlemen determine what patients pay out of pocket for prescription drugs, and it often has little to do with the actual cost of the drug itself. That’s what Gretchen Liu came to realize, when she discovered she was…

It seems every week the insurance industry is busy pointing the finger at biopharmaceutical innovators for the rising cost of health care. Of course, this public relations campaign relies on twisting some facts and completely ignoring others. For example, the insurance lobby rarely mentions that: …

Opioid abuse and addiction in America continues to ravish communities, families, and individuals across the nation. With an annual price tag exceeding $500 billion in health and social costs, solutions are needed to combat this growing problem before more damage is done. Thankfully, the…